Trial
NCT06939816
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Enyo Pharma
Collaborators
—
Condition
Chronic Kidney Disease Stage 2
Intervention
Vonafexor low dose
Why stopped
Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-23